Retrospective Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Sep 21, 2020; 26(35): 5314-5327
Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5314
Table 3 Analysis of clinical features of sA159V-positive and sA159V-negative patients
Clinical featuressA159V-positive,n = 270sA159V-negative,n = 19170Univariate,P valueUnivariate,PMultivariate,P valueMultivariate , P
Age in year46.67 ± 12.1940.72 ± 12.830.00< 0.050.00< 0.05
Gender, male214 (79.26%)15477 (80.74%)0.54> 0.050.97> 0.05
Genotype, C%/B%90.00/10.0084.31/14.820.03< 0.050.40> 0.05
HBV DNA as log10 IU/mL4.54 (3.18, 6.55)4.37(2.95, 6.27)0.09> 0.050.40> 0.05
ALT in U/L42 (25, 87)42 (26, 82)0.67> 0.050.32> 0.05
AST in U/L41 (28, 83)38 (26,71)0.33> 0.050.61> 0.05
TBIL in μmol/L16.10 (10.95, 25.45)14.30 (10.40, 22.10)0.13> 0.050.58> 0.05
CHE in U/L5940 (3114, 8091)6764 (4276, 8469)0.11> 0.050.87> 0.05
HBsAg, COI4987.83 ± 3128.435064.50 ± 2931.790.05> 0.050.15> 0.05
Coexistent with ADV-r mutation41 (15.19%)1663 (8.68%)0.00< 0.050.00< 0.05
Coexistent with LAM-r mutation97 (35.93%)5316 (27.73%)0.00< 0.050.01< 0.05
Coexistent with ETV-r mutation20 (7.41%)868 (4.53%)0.04< 0.050.40> 0.05